📊 AI Stock Rating — Summary

For Q3 2025, BIO reported revenue of $653 million with a net loss of $341.9 million, resulting in an EPS of -$12.7. Despite the loss, free cash flow was positive at $89.2 million. The company issued $4.2 million in stock but also repurchased $53.4 million and paid dividends totaling $62.7 million. Total liabilities stood at $2.96 billion against equity of $6.74 billion, with net debt reaching $193.9 million. Cash reserves were robust at $398.2 million. Analysts have a price target of $340, suggesting potential valuation upside. BIO faces notable challenges with significant losses impacting profitability. However, the firm demonstrated solid cash flow generation with a positive free cash flow figure, indicating operational efficiency. Revenue growth seems volatile given the net loss, but continued strategic buybacks suggest a commitment to enhancing shareholder value. The balance sheet shows more equity than liabilities, which speaks to financial stability. Despite the lack of reported P/E and FCF yield data, $340 analyst targets reflect underlying confidence in recovery potential. Shareholder returns are bolstered by dividends and buybacks, supplemented by cash-flow strength.

AI Score Breakdown

Revenue Growth — Score: 5/10

Revenue reached $653 million, but net income losses indicate instability in growth. Drivers remain unclear without explicit detail on performance sources.

Profitability — Score: 3/10

With a net income loss of $341.9 million and an EPS of -$12.7, profitability is under pressure. Operational efficiency is reflected in positive free cash flow, but overall margins need improvement.

Cash Flow Quality — Score: 7/10

Free cash flow was strong at $89.2 million, showing good liquidity amidst operational challenges. Dividends and buybacks highlight a focus on shareholder return despite net losses.

Leverage & Balance Sheet — Score: 6/10

Net debt is manageable at $193.9 million with considerable equity and $398.2 million in cash. However, high liabilities warrant vigilance.

Shareholder Returns — Score: 7/10

Despite losses, shareholders received value via share repurchases totaling $53.4 million and $62.7 million in dividends, showcasing a solid return strategy.

Analyst Sentiment & Valuation — Score: 6/10

Analyst price targets at $340 reflect optimism despite current losses, suggesting the stock might be undervalued if financial recovery is realized. Lack of trend data limits a deeper valuation analysis.

⚠ AI-generated — informational only, not financial advice.